drugset / Trial / NCT00057317
Study of Ro 205-2349 in Patients With Type 2 Diabetes Mellitus
RandomizedDouble-blindTreatment
Summary
The objective of the study is to determine the dose(s) of Ro 205-2349 which, when compared to placebo, are efficacious, safe and tolerable in improving glycemic control in patients with type 2 diabetes. Doses of 5 to 20 mg/day will be studied.
Timeline
- Start
- 2001-12
- Primary completion
- 2003-12
- Completion
- 2003-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RO 205-2349 | Unknown | — | — |